Sarepta Therapeutics Résultats passés
Passé contrôle des critères 0/6
Sarepta Therapeutics a connu une croissance annuelle moyenne de ses bénéfices de 28.3%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 33.4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 27.6% par an.
Informations clés
28.28%
Taux de croissance des bénéfices
31.76%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 27.60% |
| Rendement des fonds propres | -8.95% |
| Marge nette | -6.93% |
| Dernière mise à jour des bénéfices | 30 Jun 2026 |
Mises à jour récentes des performances passées
Recent updates
Seeking Alpha • Aug 28
Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution
Summary Sarepta Therapeutics remains a hold as ELEVIDYS uptake faces operational friction, keeping the stock in a discounted, execution-risk bucket. 2Q26 revenue declined 34% YoY to $401.3M, but cost discipline drove positive GAAP operating income and improved profitability despite top-line weakness. ELEVIDYS is the core value driver, yet its commercial ramp is complex, capacity-constrained, and not delivering the clean acceleration required for re-rating. Valuation appears optically cheap at 1.1x forward sales, but the market discounts durability and execution risk, awaiting proof of scalable, predictable revenue growth. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 10
SRPT: 2027 Duchenne Decision Will Pressure Shares Despite Conflicted Street Views
The updated analyst fair value estimate for Sarepta Therapeutics has edged higher to about $7.02 per share. This revision is supported by recent price target updates that reflect adjustments to Elevidys revenue expectations and differing views on the implications of upcoming regulatory and data catalysts.Mise à jour du récit • Jun 23
SRPT: Thin siRNA Data And Regulatory Shifts Will Pressure Overvalued Shares
Sarepta Therapeutics’ analyst price target has been reduced by $1 to $19. Analysts cite a slightly higher discount rate, a marginally weaker revenue growth outlook and a small trim to projected profit margins, partly offset by updated P/E assumptions.Article d’analyse • Jun 21
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies
Recent commentary around Sarepta Therapeutics (SRPT) focuses on Elevidys, its gene therapy for Duchenne muscular dystrophy, with expectations of near term stabilization and renewed attention on the company’s siRNA pipeline and the evolving FDA stance. See our latest analysis for Sarepta Therapeutics. The recent focus on Elevidys and Sarepta Therapeutics’ siRNA programs comes after a mixed share price record, with a 14.5% 7 day share price return and year to date share price performance down...Mise à jour du récit • Jun 06
SRPT: Thin siRNA Data And Regulatory Risks Will Pressure Overvalued Shares
Analysts have trimmed their average price target on Sarepta Therapeutics by $1 to $19, reflecting updated views on fair value, a slightly higher discount rate, and revised expectations for revenue growth, margins, and future P/E multiples. Analyst Commentary Recent research on Sarepta Therapeutics shows a split view, with some firms lifting price targets while others turning more cautious.
Mise à jour du récit • May 23
SRPT: 2026 Guidance And siRNA Data Readouts Will Drive Upside Potential
Analysts trimmed Sarepta Therapeutics' average price target by $1 to $19, reflecting updated models that factor in revised 2026 guidance, a higher assumed discount rate, lower projected profit margins, and a higher future P/E multiple. Analyst Commentary Bullish analysts remain divided on Sarepta, but several recent research updates still point to constructive sentiment around execution on guidance, product launches, and the pipeline.Article d’analyse • May 14
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News
Investors appear disappointed with Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) recent earnings, despite the decent...Mise à jour du récit • May 07
SRPT: 2026 Reset Year Guidance Will Pressure Overvalued Shares
Analysts have lowered their average price target on Sarepta Therapeutics by about $64. The change is tied to updated 2026 guidance, reduced revenue expectations for Elevidys and PMO products, and a lower future P/E assumption, despite generally mixed views on the siRNA and DM1 programs.Mise à jour du récit • Apr 22
SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential
Sarepta Therapeutics' updated analyst price target has shifted modestly, reflecting a lower fair value estimate of $37.42 and a reduced future P/E assumption as analysts weigh mixed siRNA data, updated 2026 revenue guidance, and varying views on Elevidys and the PMO franchise. Analyst Commentary Recent Street research on Sarepta shows a wide range of views, but several bullish analysts are leaning into updated company guidance and new clinical datapoints when revisiting their models.
Mise à jour du récit • Apr 07
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Analysts have lifted the blended price target for Sarepta Therapeutics by about $1 to $2, reflecting recent target revisions that balance cautious views on Elevidys revenue guidance and siRNA data quality with more constructive perspectives on early DM1 results and updated 2026 sales and expense models. Analyst Commentary Recent research paints a mixed picture for Sarepta, with analysts updating models around Elevidys, siRNA programs, and early DM1 data.Mise à jour du récit • Mar 23
SRPT: Future Upside Will Hinge On 2026 Gene Therapy Launch Reset
Analysts made a modest upward adjustment to Sarepta Therapeutics' fair value estimate, reflecting updated models around Elevidys launch pacing, 2026 revenue guidance, and revised expectations for profitability and future P/E multiples following recent Q4 results and regulatory commentary. Analyst Commentary Street research on Sarepta around the Q4 update and 2026 guidance reflects a wide range of views on execution risk, Elevidys launch pacing, and the durability of the exon-skipping and gene therapy portfolio.Mise à jour du récit • Mar 09
SRPT: Future Upside Will Depend On 2026 Gene Therapy Execution
The analyst price target for Sarepta Therapeutics has moved slightly lower to align with revised 2026 revenue expectations and product launch assumptions, with recent Street targets stepping down in a range from about $45 to $8 as analysts recalibrate Elevidys and other franchise contributions. Analyst Commentary Street views on Sarepta are split, with several firms cutting price targets after management issued 2026 revenue guidance that appears lower than earlier assumptions, while others still see room for execution on the Elevidys and exon-skipping franchises to support value over time.Mise à jour du récit • Feb 22
SRPT: Future Risk Reward Will Hinge On Elevidys Execution And Patent Overhang
The analyst price target for Sarepta Therapeutics has been raised by about $0.80. Analysts point to slightly higher fair value estimates, a modestly firmer long term profit margin outlook and updated P/E assumptions, even as they factor in a slightly higher discount rate and restrained revenue expectations.Mise à jour du récit • Feb 08
SRPT: Upcoming 2026 Clinical And Regulatory Milestones Will Drive Future Upside
Analysts have edged their price targets on Sarepta Therapeutics higher, with a modest fair value increase of about $0.20 per share. Slightly stronger long run profit expectations more than offset softer modeled revenue growth and a small trim to the assumed future P/E multiple.Mise à jour du récit • Jan 25
SRPT: Gene Therapy Catalysts And Access Updates Will Drive Future Upside
Analysts nudged their price target on Sarepta Therapeutics slightly higher, lifting fair value by about US$0.33 to US$39.90 as they factor in updated expectations for Elevidys sales, profitability, and a modestly higher discount rate. Analyst Commentary Recent research on Sarepta highlights a split view on Elevidys, with some pointing to softer near term sales and others focusing on what they see as growing adoption and a broader pipeline story.Mise à jour du récit • Jan 10
SRPT: Elevidys Adoption And Pipeline Progress Will Drive Future Upside
Analysts have reset their fair value estimate for Sarepta Therapeutics from US$55.90 to US$39.56. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple following recent research that highlights both improved confidence in Elevidys adoption and ongoing caution from some covering firms.Mise à jour du récit • Dec 25
SRPT: Future Risk Reward Will Hinge On Evolving Safety And Coverage Decisions
The analyst price target for Sarepta Therapeutics has been raised slightly, by about $0.20 per share. Analysts attribute this to stronger than expected Elevidys adoption, supportive payer coverage, and a more favorable risk and reward profile, despite unchanged long-term growth and margin assumptions.Mise à jour du récit • Dec 11
SRPT: Safety Reviews And Payer Decisions Will Shape Future Risk Reward Balance
Sarepta Therapeutics' fair value estimate has been raised modestly to approximately $20.43 from $19.91, as analysts factor in stronger than expected Elevidys adoption and a more favorable risk or reward profile, despite only incremental improvements in revenue growth and discount rate assumptions. Analyst Commentary Street research on Sarepta has turned more constructive at the margin, with multiple models recalibrated around stronger Elevidys uptake and a clearer path to reimbursement.Article d’analyse • Dec 04
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders would be excited to see that the share price has had a great...Mise à jour du récit • Nov 27
SRPT: Ongoing Regulatory Reviews And Safety Updates Will Shape Near-Term Prospects
The analyst price target for Sarepta Therapeutics has been modestly reduced from approximately $21.55 to $19.91. Analysts express mixed expectations based on recent shifts in profit margin projections and ongoing evaluations of Elevidys adoption and safety dynamics.Mise à jour du récit • Nov 05
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Sarepta Therapeutics' analyst price target has been revised downward from approximately $22.88 to $21.55 per share. Analysts cite ongoing concerns over Elevidys uptake, modest improvements to revenue outlook, and persistent profit margin pressures.Article d’analyse • Oct 18
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry
Despite an already strong run, Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares have been powering on, with a gain of...Mise à jour du récit • Sep 26
Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ consensus price target has been lowered from $23.96 to $22.88, primarily due to ongoing Elevidys safety concerns, regulatory uncertainty, and negative sentiment over recent management decisions, outweighing the short-term relief from improved liquidity and regulatory clarity. Analyst Commentary Elevidys safety concerns, including recent patient deaths and new serious adverse event reports, have sustained regulatory uncertainty and contributed to ongoing negative sentiment and price target reductions by Bearish analysts.Mise à jour du récit • Sep 04
Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ price target remains under pressure due to persistent safety concerns and regulatory uncertainty surrounding Elevidys, limited market scope after clinical setbacks and halted non-ambulatory development, and skepticism about long-term cash generation, resulting in a maintained consensus analyst price target of $23.84. Analyst Commentary Continued safety concerns surrounding Elevidys, particularly following patient deaths and serious adverse events (notably acute liver failure in non-ambulatory patients and new adverse event reports), have caused repeated reductions in revenue forecasts and increased uncertainty about regulatory approval and commercial uptake.Article d’analyse • May 29
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
Key Insights Sarepta Therapeutics to hold its Annual General Meeting on 5th of June CEO Doug Ingram's total...Article d’analyse • May 08
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
Today is shaping up negative for Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders, with the analysts delivering...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Sarepta Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 26 | 1,974 | -137 | 437 | 0 |
| 31 Mar 26 | 2,184 | 65 | 467 | 0 |
| 31 Dec 25 | 2,198 | -713 | 492 | 0 |
| 30 Sep 25 | 2,414 | -272 | 527 | 0 |
| 30 Jun 25 | 2,482 | -58 | 564 | 0 |
| 31 Mar 25 | 2,233 | -248 | 564 | 0 |
| 31 Dec 24 | 1,902 | 235 | 558 | 0 |
| 30 Sep 24 | 1,640 | 122 | 526 | 0 |
| 30 Jun 24 | 1,505 | 47 | 518 | 0 |
| 31 Mar 24 | 1,403 | 17 | 498 | 0 |
| 31 Dec 23 | 1,243 | -536 | 482 | 0 |
| 30 Sep 23 | 1,105 | -691 | 471 | 0 |
| 30 Jun 23 | 1,003 | -908 | 455 | 0 |
| 31 Mar 23 | 976 | -1,115 | 490 | 0 |
| 31 Dec 22 | 933 | -703 | 451 | 0 |
| 30 Sep 22 | 876 | -716 | 409 | 0 |
| 30 Jun 22 | 835 | -507 | 365 | 0 |
| 31 Mar 22 | 766 | -357 | 283 | 0 |
| 31 Dec 21 | 702 | -419 | 283 | 0 |
| 30 Sep 21 | 646 | -486 | 291 | 0 |
| 30 Jun 21 | 600 | -634 | 305 | 0 |
| 31 Mar 21 | 573 | -704 | 306 | 0 |
| 31 Dec 20 | 540 | -554 | 318 | 0 |
| 30 Sep 20 | 495 | -601 | 313 | 0 |
| 30 Jun 20 | 450 | -530 | 313 | 0 |
| 31 Mar 20 | 407 | -656 | 307 | 0 |
| 31 Dec 19 | 381 | -715 | 285 | 0 |
| 30 Sep 19 | 365 | -620 | 268 | 0 |
| 30 Jun 19 | 345 | -570 | 245 | 0 |
| 31 Mar 19 | 323 | -403 | 227 | 0 |
| 31 Dec 18 | 301 | -362 | 208 | 0 |
| 30 Sep 18 | 274 | -245 | 178 | 0 |
| 30 Jun 18 | 241 | -216 | 153 | 0 |
| 31 Mar 18 | 203 | -170 | 133 | 0 |
| 31 Dec 17 | 155 | -51 | 123 | 166 |
| 30 Sep 17 | 103 | -115 | 105 | 0 |
| 30 Jun 17 | 57 | -124 | 99 | 0 |
| 31 Mar 17 | 22 | -123 | 87 | 0 |
| 31 Dec 16 | 5 | -267 | 81 | 0 |
| 30 Sep 16 | 1 | -243 | 85 | 0 |
| 30 Jun 16 | 1 | -239 | 78 | 0 |
| 31 Mar 16 | 1 | -218 | 73 | 0 |
| 31 Dec 15 | 1 | -220 | 66 | 0 |
| 30 Sep 15 | 0 | -200 | 55 | 0 |
Des revenus de qualité: SRPT n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: SRPT n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SRPT n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 28.3% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de SRPT au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: SRPT n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 64.6% ).
Rendement des fonds propres
ROE élevé: SRPT a un retour sur capitaux propres négatif ( -8.95% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/21 23:28 |
| Cours de l'action en fin de journée | 2026/09/21 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Sarepta Therapeutics, Inc. est couverte par 48 analystes. 19 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |